IL6 and plasma cell myeloma: Bortezomib decreases the adhesion of the myeloma plasma cell to stromal cells, which increases sensitivity to apoptosis, as well as interrupts prosurvival paracrine and autocrine cytokine loops in the bone marrow microenvironment mediated by IL-6, IGF1, VEGF and TNFα (Hideshima et al, 2001).